Premium
MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)
Author(s) -
Hill B.T.,
Switchenko J.M.,
Martin P.,
Churnetski M.C.,
Sawalha Y.,
Goyal S.,
Shanmugasundaram K.,
Calzada O.,
Kolla B.,
Bachanova V.,
Gerson J.N.,
Barta S.K.,
Maldonado E.,
Gordon M.,
Danilov A.,
Grover N.S.,
Mathews S.,
Burkart M.,
Karmali R.,
Ghosh N.,
Park S.I.,
Epperla N.,
Bond D.A.,
Badar T.,
Blum K.A.,
Guo J.,
Hamadani M.,
Fenske T.S.,
Malecek M.,
Maddocks K.,
Flowers C.R.,
Kahl B.S.,
Cohen J.B.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.75_2631
Subject(s) - medicine , rituximab , bendamustine , mantle cell lymphoma , autologous stem cell transplantation , population , maintenance therapy , surgery , oncology , gastroenterology , lymphoma , chemotherapy , environmental health